Date published: 2026-1-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

Vmn1r17 Inhibitors

Vmn1r17 inhibitors represent a specialized group of molecules designed to interact with and inhibit the activity of the Vmn1r17 receptor. The Vmn1r17 receptor is part of the vomeronasal receptor family, specifically within the type 1 vomeronasal receptor class (Vmn1r), which is involved in pheromone detection and plays a role in olfactory signaling pathways. These receptors are typically located in the vomeronasal organ (VNO), a sensory organ found in many animals that detects chemical cues from the environment, leading to various physiological responses. The role of Vmn1r17 inhibitors is to reduce or block the interaction between Vmn1r17 receptors and their specific ligands, thereby modulating the biochemical pathways associated with pheromone detection. These inhibitors are designed with high specificity for the Vmn1r17 receptor, allowing for the selective study of this receptor's function and its signaling mechanisms.

Vmn1r17 inhibitors may belong to various structural classes, depending on their mode of binding and molecular configuration. Some inhibitors could act by competing with natural ligands at the binding site, while others may work through allosteric mechanisms, altering the receptor's conformational state and its signaling capacity. Structural studies and biochemical analyses of Vmn1r17 inhibitors allow researchers to better understand the receptor's binding affinities, conformational changes, and downstream effects on olfactory signaling pathways. These inhibitors are valuable tools in research aimed at dissecting the precise role of Vmn1r17 in pheromone detection, with their applications mainly focused on studying receptor-ligand interactions and the overall biochemical communication processes involved in olfaction.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

Beta-adrenergic receptor antagonist, can modulate GPCR signaling potentially affecting Vmn1r17 indirectly.

Cimetidine

51481-61-9sc-202996
sc-202996A
5 g
10 g
$62.00
$86.00
1
(1)

Histamine H2 receptor antagonist, may alter GPCR-mediated processes potentially impacting Vmn1r17.

Ondansetron

99614-02-5sc-201127
sc-201127A
10 mg
50 mg
$82.00
$333.00
1
(0)

Serotonin receptor antagonist, might affect GPCR signaling pathways influencing Vmn1r17 indirectly.

Yohimbine hydrochloride

65-19-0sc-204412
sc-204412A
sc-204412B
1 g
5 g
25 g
$51.00
$171.00
$530.00
2
(1)

Alpha-2 adrenergic receptor antagonist, could affect noradrenergic signaling potentially related to Vmn1r17.

Losartan

114798-26-4sc-353662
100 mg
$130.00
18
(1)

Angiotensin II receptor antagonist, might modulate GPCR pathways potentially influencing Vmn1r17 activity.

Verapamil

52-53-9sc-507373
1 g
$374.00
(0)

Calcium channel blocker, could affect calcium signaling pathways potentially related to Vmn1r17.

Pertussis Toxin (islet-activating protein)

70323-44-3sc-200837
50 µg
$451.00
3
(1)

Inhibits Gi/o proteins, could affect GPCR-mediated signaling pathways involved with Vmn1r17.

Amiloride

2609-46-3sc-337527
1 g
$296.00
7
(1)

Sodium channel blocker, might indirectly influence signaling mechanisms relevant to Vmn1r17.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

PI3K inhibitor, could affect downstream signaling pathways that might impact Vmn1r17 function.

Haloperidol

52-86-8sc-507512
5 g
$190.00
(0)

Dopamine receptor antagonist, might influence GPCR-mediated signaling pathways related to Vmn1r17.